Clinical Trials Browser

Phase 1/2 × utomilumab × Gynecologic × Clear all

NCT03318900 2024-11-07

T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

Phase 1/2 Completed

5 enrolled 8 charts

Ovarian Neoplasms